School of Medicine


Showing 981-1,000 of 1,059 Results

  • Samantha Wang

    Samantha Wang

    Clinical Assistant Professor, Medicine

    BioSamantha Wang earned her Bachelors degree in Molecular & Cell Biology from the University of California, Berkeley, followed by MD and Masters in Health Science degrees from Yale University School of Medicine. After completing her internal medicine residency at Stanford, Dr. Wang served as Chief Resident for the Internal Medicine Residency and subsequently joined the Division of Hospital Medicine, where she now contributes her expertise in the care of acutely ill adult patients.

    Outside her clinical work, Dr. Wang is deeply committed to medical education, health equity, and patient-centered communication. She has been recognized for her exceptional teaching with the David A. Rytand Teaching Award, and subsequently completed a Rathmann Family Foundation Fellowship in Medical Education in Patient-Centered Care. With leadership roles in both undergraduate and graduate medical education programs, Dr. Wang is actively engaged and committed in shaping the future of health care professionals.

    Dr. Wang is deeply passionate about health equity and has spoken nationally on the topic of racial justice in clinical decision-making. She has received institutional and national funding to develop and study health equity curricula across the continuum of medical education, and is the course director for the "5-Minute Moment for Racial Justice", which advocates for justice, equity, diversity, and inclusion in medical decision making. As a member of the Stanford 25 Bedside Medicine and Presence Groups, she strives to create a more equitable and inclusive learning environment. In her research endeavors, Samantha employs a comprehensive approach, utilizing quantitative and qualitative methodologies, alongside participatory qualitative approaches with community partners. Her focus is on understanding how to effectively teach health equity in the clinical learning environment.

    Her quality improvement work is centered on improving communication skills around serious illness diagnoses, and she has trained students, residents, and other faculty members in these skills. Dr. Wang believes that the best doctors combine intellectual acumen with the ability to connect with patients on a personal level, bringing thoughtfulness, kindness, and authenticity to the bedside. In her care of complex patients with serious diagnoses, she consistently advocates for incorporating loved ones' and the patient's values into the care plan, ensuring a holistic and patient-centered approach.

  • Shan X. Wang

    Shan X. Wang

    Leland T. Edwards Professor in the School of Engineering and Professor of Electrical Engineering and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)

    Current Research and Scholarly InterestsShan Wang was named the Leland T. Edwards Professor in the School of Engineering in 2018. He directs the Center for Magnetic Nanotechnology and is a leading expert in biosensors, information storage and spintronics. His research and inventions span across a variety of areas including magnetic biochips, in vitro diagnostics, cancer biomarkers, magnetic nanoparticles, magnetic sensors, magnetoresistive random access memory, and magnetic integrated inductors.

  • Sui Wang, PhD

    Sui Wang, PhD

    Assistant Professor of Ophthalmology

    Current Research and Scholarly InterestsOur research focuses on unraveling the molecular mechanisms underlying retinal development and diseases. We employ genetic and genomic tools to explore how various retinal cell types, including neurons, glia, and the vasculature, respond to developmental cues and disease insults at the epigenomic and transcriptional levels. In addition, we investigate their interactions and collective contributions to maintain retinal integrity.

    1. Investigating retinal development:
    We utilize genetic tools and methods such as in vivo plasmid electroporation and CRISPR to dissect the roles of cis-regulatory elements and transcription factors in controlling retinal development.

    2. Understanding diabetes-induced cell-type-specific responses in the retina:
    Diabetes triggers a range of multicellular responses in the retina, such as vascular lesions, glial dysfunction, and neurodegeneration, all of which contribute to retinopathy. We delve into the detailed molecular mechanisms underlying these diabetes-induced cell-type-specific responses and the pathogenesis of diabetic retinopathy.

    3. Developing molecular tools for labeling and manipulation of specific cell types in vivo:
    Cis-regulatory elements, particularly enhancers, play pivotal roles in directing tissue- and cell-type-specific expression. Our interest lies in identifying enhancers that can drive cell type-specific expression in the retina and brain. We incorporate these enhancers into plasmid or AAV-based delivery systems, enabling precise labeling and manipulation of specific cell types in vivo.

  • Taia T. Wang, MD, PhD, MSCI

    Taia T. Wang, MD, PhD, MSCI

    Assistant Professor of Medicine (Infectious Diseases) and of Microbiology and Immunology

    Current Research and Scholarly InterestsLaboratory of Mechanisms in Human Immunity and Disease Pathogenesis

    Antibodies are a critical component of host defense. While the importance of humoral immunity has been recognized for decades, substantial gaps in knowledge remain around how antibodies function, and how their function is regulated, in vivo. Our laboratory performs studies designed to fill in these gaps, with the goal of enabling new vaccine and therapeutic strategies to prevent human disease. My interest in this area culminated from training in medicine, RNA virus biology (PhD), and molecular antibody biology (postdoctoral training). The intersection of these topics, viral immunity and disease pathogenesis, is the focus of our work. The essential question driving our research is why a small subset of people develop severe or fatal disease during viral infection while most infections result in a subclinical or mild outcome, even in at-risk populations. Our hypothesis is that the antibody signaling pathways that are engaged during viral infection through Fc gamma receptors (FcγRs) are a key driver of these distinct outcomes. We are focused on several major unknowns to address this hypothesis: How are antibody effector functions regulated in vivo and does this change in disease? How do distinct signaling pathways engaged by IgG immune complex-FcγR interactions impact host cell genetic regulation and the ultimate inflammatory/immune response? What are the tissue-specific functions that antibodies engage? How does the heterogeneity in post-translational modifications (PTMs) of human antibodies contribute to heterogeneity in viral immunity?



    Current clinical studies:
    Recruiting:

    An Open Label Study of IgG Fc Glycan Composition in Human Immunity
    Principal Investigator: Taia T. Wang, MD, PhD
    ClinicalTrials.gov Identifier:
    NCT01967238

  • Wenjun Wang

    Wenjun Wang

    Postdoctoral Scholar, Stem Cell Transplantation

    Current Research and Scholarly InterestsMy postdoctoral research focuses on investigating novel therapy for childhood leukemias.

  • Xinnan Wang

    Xinnan Wang

    Associate Professor of Neurosurgery

    Current Research and Scholarly InterestsMechanisms underlying mitochondrial dynamics and function, and their implications in neurological disorders.

  • Victoria Ward

    Victoria Ward

    Clinical Associate Professor, Pediatrics

    Current Research and Scholarly InterestsGlobal child health, digital health, preterm birth, human trafficking

  • Katja Gabriele Weinacht, MD, PhD

    Katja Gabriele Weinacht, MD, PhD

    Assistant Professor of Pediatrics (Stem Cell Transplantation and Regenerative Medicine)

    Current Research and Scholarly InterestsPediatric Hematopoietic Stem Cell Transplantation
    DiGeorge Syndrome
    Genetic Immune Diseases
    Immune Dysregulation

  • Alexis Thomas Weiner

    Alexis Thomas Weiner

    Postdoctoral Scholar, Pathology

    Current Research and Scholarly InterestsThe planar cell polarity (PCP) signaling pathway polarizes animal cells along an axis parallel to the tissue plane, and in so doing generates long-range organization that can span entire tissues. Although its core proteins and much about their interactions are known, how PCP signaling occurs at a mechanistic level remains fundamentally mysterious. In my current project I will employ novel genetic methods to dissect the logic underlying how cellular asymmetry arises at a molecular level.

  • Dana Weintraub

    Dana Weintraub

    Clinical Associate Professor, Pediatrics - General Pediatrics

    Current Research and Scholarly InterestsResearch interests include: 1) Childhood obesity, community-based interventions to increase physical activity 2) Impact of medical-legal collaboration on child and family health.

  • Irving Weissman

    Irving Weissman

    Virginia & D.K. Ludwig Professor of Clinical Investigation in Cancer Research, Professor of Pathology, and of Developmental Biology

    Current Research and Scholarly InterestsStem cell and cancer stem cell biology; development of T and B lymphocytes; cell-surface receptors for oncornaviruses in leukemia. Hematopoietic stem cells; Lymphocyte homing, lymphoma invasiveness and metastasis; order of events from hematopoietic stem cells [HSC] to AML leukemia stem cells and blood diseases, and parallels in other tissues; discovery of tumor and pathogenic cell 'don't eat me' and 'eat me' signals, and translation into therapeutics.

  • Marius Wernig

    Marius Wernig

    Professor of Pathology and, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsEpigenetic Reprogramming, Direct conversion of fibroblasts into neurons, Pluripotent Stem Cells, Neural Differentiation: implications in development and regenerative medicine

  • Matthew Wheeler

    Matthew Wheeler

    Associate Professor of Medicine (Cardiovascular Medicine)

    Current Research and Scholarly InterestsTranslational research in rare and undiagnosed diseases. Basic and clinical research in cardiomyopathy genetics, mechanisms, screening, and treatment. Investigating novel agents for treatment of hypertrophic cardiomyopathy and new mechanisms in heart failure. Cardiovascular screening and genetics in competitive athletes, disease gene discovery in cardiomyopathy and rare disease. Informatics approaches to rare disease and multiomics. Molecular transducers of physical activity bioinformatics.

  • Nolan Williams

    Nolan Williams

    Associate Professor of Psychiatry and Behavioral Sciences (Major Laboratories & Clinical Translational Neurosciences Incubator) and, by courtesy, of Radiology (Neuroimaging and Neurointervention)

    BioNolan Williams, M.D. is an Associate Professor of Psychiatry and Behavioral Sciences at Stanford University and Director of the Stanford Brain Stimulation Lab. The long-term goals of his research program are to develop innovative technologies and therapeutics capable of modulating the neural circuitry disrupted in mood disorders, OCD, and other neuropsychiatric conditions. His team has been developing neuroimaging-based approaches to precisely target therapeutic delivery and predict treatment responses to therapeutic neuromodulation and psychedelics. Dr. Williams earned his M.D. and completed his dual residencies in neurology and psychiatry at the Medical University of South Carolina (MUSC). Triple board-certified in general neurology, general psychiatry, as well as behavioral neurology and neuropsychiatry, Dr. Williams brings a comprehensive background in clinical neuroscience to his role as a clinically active neuropsychiatrist. His expertise extends to the development and implementation of novel therapeutics, including devices and novel compounds, for central nervous system illnesses.
    Over the past decade, Dr. Williams’ laboratory alongside collaborators at Stanford University have pioneered multiple novel therapeutic and human neuroscience approaches. Notably, Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) is the world's first non-invasive, rapid-acting neuromodulation approach for treatment-resistant depression. SAINT received FDA Breakthrough Device Designation Status (2021) and FDA Clearance (2022) and is the first psychiatric treatment to be covered by Medicare New Technology Add-On Payment (NTAP). As of April 2024, SAINT has been reimbursed for patients suffering from severe depression within inpatient psychiatric units. The SAINT technology is being deployed both clinically and in research protocols in laboratories and hospitals worldwide. Dr. Williams also has an expertise in psychedelic medicines for neuropsychiatric illness and is the first investigator to conduct mechanistic clinical trials exploring the neurobiological effects of ibogaine.
    His research accomplishments have garnered international recognition, earning prestigious awards from the Pritzker Neuropsychiatric Disorders Consortium, One Mind Institute, Wellcome Leap Foundation, International Brain Stimulation Conference, National Institute of Mental Health (Biobehavioral Research Award for Innovative New Scientists), Society of Biological Psychiatry (A. E. Bennett Award), along with multiple awards from the Brain Behavior Research Foundation (most notably the Gerald L. Klerman Award). His work has been featured in Scientific American, The New York Times, The Washington Post, USA Today, CBS Sunday Morning, and the TODAY Show.

  • Darrell Wilson

    Darrell Wilson

    Professor of Pediatrics (Endocrinology) at the Lucile Salter Packard Children's Hospital, Emeritus

    Current Research and Scholarly InterestsMy research interests cover a number of areas in Pediatric Endocrinology and Diabetes. I am PI of the Stanford Center for the NIH-funded Type-1 Diabetes TrialNet group. TrialNet conducts clinical trials directed at preventing or delaying the onset of Type 1 diabetes. I am an investigator in DirecNet, another NIH-funded study group, which is devoted to evaluating glucose sensors and the role of technology on the management of diabetes.